An In Vivo Self‐Assembled Bispecific Nanoblocker for Enhancing Tumor Immunotherapy
Authors:
- 9 October 2023
- journal article
- research article
- Published by Wiley in Advanced Materials
- Vol. 35 (45) , e2303831
Abstract
Anti‐PD‐L1 monoclonal antibody has achieved substantial success in tumor immunotherapy by T‐cells activation. However, the excessive accumulation of extracellular matrix components induced by unsatisfactory T‐cells infiltration and poor tumor penetration of antibodies make it challenging to realize efficient tumor immunotherapy. Herein, a peptide‐based bispecific nanoblocker (BNB) strategy is reported for in situ construction of CXCR4/PD‐L1 targeted nanoclusters on the surface of tumor cells that are capable of boosting T‐cells infiltration through CXCR4 blockage and enhancing T‐cells activation by PD‐L1 occupancy, ultimately realizing high‐performance tumor immunotherapy. Briefly, the BNB strategy selectively recognizes and bonds CXCR4/PD‐L1 with deep tumor penetration, which rapidly self‐assembles into nanoclusters on the surface of tumor cells. Compared to the traditional bispecific antibody, BNB exhibits an intriguing metabolic behavior, that is, the elimination half‐life (t1/2) of BNB in the tumor is 69.3 h which is ≈50 times longer than that in the plasma (1.4 h). The higher tumor accumulation and rapid systemic clearance overcome potential systemic side effects. Moreover, the solid tumor stress generated by excessive extracellular matrix components is substantially reduced to 44%, which promotes T‐cells infiltration and activation for immunotherapy efficacy. Finally, these findings substantially strengthen and extend clinical applications of PD‐1/PD‐L1 immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (52003270, 52273126)
- National Key Research and Development Program of China (2020YFA0210800, 2021YFB3801000)
This publication has 39 references indexed in Scilit:
- Targeting CXCL12/CXCR4 Axis in Tumor ImmunotherapyCurrent Medicinal Chemistry, 2019
- Bispyrene-Based Self-Assembled Nanomaterials: In Vivo Self-Assembly, Transformation, and Biomedical EffectsAccounts of Chemical Research, 2019
- Self‐Assembled Peptide‐Based Nanomaterials for Biomedical Imaging and TherapyAdvanced Materials, 2018
- Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancerProceedings of the National Academy of Sciences, 2017
- Regulation of PD-L1: a novel role of pro-survival signalling in cancerAnnals of Oncology, 2015
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- In Situ Formation of Nanofibers from Purpurin18‐Peptide Conjugates and the Assembly Induced Retention Effect in Tumor SitesAdvanced Materials, 2015
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancerProceedings of the National Academy of Sciences, 2013
- Structure-Based Development of Antagonists for Chemokine Receptor CXCR4Current Computer-Aided Drug Design, 2013
- Causes, consequences, and remedies for growth-induced solid stress in murine and human tumorsProceedings of the National Academy of Sciences, 2012